N/A N=80 Randomized Double-blind Treatment

Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty

Posterior Knee Infiltration

Bottom Line

View on ClinicalTrials.gov: NCT02701296 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2017

Primary outcome: Primary: Pain Intensity — 3.5; 3.2; 2.1; 1.5 pain score

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Ropivacaine with Epinephrine (Drug); Ropivacaine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Trinity Health Of New England
Primary completion: Aug 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Pain Intensity	3.5; 3.2; 2.1; 1.5; 1.9; 2.0	—
SECONDARY Opioid Consumption	0.33; 0.42	—
SECONDARY Plantar Flexion in the Tibial Nerve Distribution	1; 0; 3; 25; 38; 11	—
SECONDARY Cold Sensation in the Tibial Nerve Distribution	1; 6; 7; 27; 34; 3	—
SECONDARY Dorsiflexion in the Peroneal Nerve Distribution	0; 0; 1; 4; 41; 32	—
SECONDARY Sensation in the Peroneal Nerve Distribution	2; 1; 3; 11; 37; 24	—

Summary

To assess pain control after total knee replacement surgery using two different nerve block techniques. The 2 methods are: 1. Continuous femoral nerve block with ultrasound guided posterior capsular injection 2. Continuous femoral nerve block with ultrasound selective tibial nerve block.

Eligibility Criteria

Inclusion Criteria

Patients having primary, unilateral total knee arthroplasty
Age 18-80

Exclusion Criteria

History of neurologic disease, neuropathy, diabetes, or major systemic illness
Allergy to local anesthetic solution or NSAIDs
Pregnancy
Chronic use of narcotics
Inability to give consent/cooperate with study

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02701296). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.